Envestnet Asset Management Inc. increased its position in Meridian Bioscience, Inc. (NASDAQ:VIVO – Get Rating) by 0.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 41,308 shares of the company’s stock after purchasing an additional 341 shares during the period. Envestnet Asset Management Inc. owned 0.09% of Meridian Bioscience worth $1,257,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. grew its stake in Meridian Bioscience by 41.6% in the second quarter. Assenagon Asset Management S.A. now owns 180,170 shares of the company’s stock worth $5,481,000 after purchasing an additional 52,963 shares during the period. Campbell & CO Investment Adviser LLC grew its stake in Meridian Bioscience by 15.4% in the first quarter. Campbell & CO Investment Adviser LLC now owns 12,813 shares of the company’s stock worth $333,000 after purchasing an additional 1,713 shares during the period. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in Meridian Bioscience in the first quarter worth $1,290,000. AdvisorShares Investments LLC purchased a new stake in Meridian Bioscience in the first quarter worth $299,000. Finally, Advisor Group Holdings Inc. grew its stake in Meridian Bioscience by 6.1% in the first quarter. Advisor Group Holdings Inc. now owns 16,453 shares of the company’s stock worth $464,000 after purchasing an additional 940 shares during the period. 93.65% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Separately, StockNews.com cut Meridian Bioscience from a “buy” rating to a “hold” rating in a research note on Saturday.
Meridian Bioscience Trading Down 0.7 %
Meridian Bioscience Profile
Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare brands; and urea breath testing for H.
- Get a free copy of the StockNews.com research report on Meridian Bioscience (VIVO)
- After Nixing its 13% Dividend, Is Lumen Technologies Okay To Own?
- Cisco Systems Hopes Restructuring Cuts Costs to Drive Revenue
- The Sell-Side Caps Gains In Dick’s Sporting Goods
- Want to Get a 10% Dividend Yield, Look Here
- Stock-ing Stuffers: 3 Attractive Stocks Trading Around $10
Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.